The report analyzes and forecasts the diabetes drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of diabetes drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major diabetes drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of diabetes drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of diabetes drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global diabetes drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the diabetes drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of diabetes drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive Landscape
The report also profiles major players in the Diabetes drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.
Diabetes Drugs Market has been segmented as given below:
Diabetes Drugs Market, by Therapy
Diabetes Drugs Market, by Disease Type
Diabetes Drugs Market, by Distribution Channel
Diabetes Drugs Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Secondary Research Methodology
2.2. Primary Research Methodology
2.3. Analysis Research Methodology
2.4. Final Report & Conclusions Research Methodology
3. Executive Summary: Global Diabetes Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Therapy Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/Technology Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.3. Opportunity Analysis
4.4.4. Trends
4.5. Global Diabetes Drugs Market Analysis and Forecasts, 2017–2027
4.6. Porter’s Five Forces Analysis
4.7. Value Chain Analysis
4.8. Pipeline Analysis
5. Global Diabetes Drugs Market Analysis and Forecasts, By Therapy
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast by Therapy, 2017–2027
5.4.1. Glucagon-like peptide-1 (GLP-1) agonist
5.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
5.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
5.4.4. Insulin
5.4.5. Others
5.5. Market Attractiveness by Therapy
6. Global Diabetes Drugs Market Analysis and Forecasts, By Disease Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast by Disease Type, 2017–2027
6.4.1. Type 1 Diabetes
6.4.2. Type 2 Diabetes
6.4.3. Gestational Diabetes
6.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
6.5. Disease Type Comparison Matrix
6.6. Market Attractiveness by Disease Type
7. Global Diabetes Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast by Distribution Channel, 2017–2027
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.5. Distribution Channel Comparison Matrix
7.6. Market Attractiveness by Distribution Channel
8. Global Diabetes Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Middle East & Africa
8.3.5. Latin America
8.4. Market Attractiveness by Country/Region
9. North America Diabetes Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market Value Forecast by Therapy, 2017–2027
9.2.1. Glucagon-like peptide-1 (GLP-1) agonist
9.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
9.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
9.2.4. Insulin
9.2.5. Others
9.3. Market Value Forecast by Disease Type, 2017–2027
9.3.1. Type 1 Diabetes
9.3.2. Type 2 Diabetes
9.3.3. Gestational Diabetes
9.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
9.4. Market Value Forecast by Distribution Channel, 2017–2027
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast by Country, 2017–2027
9.5.1. U. S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. by Therapy
9.6.2. by Disease Type
9.6.3. by Distribution Channel
9.6.4. by Country
9.7. Key Trends
10. Europe Diabetes Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Value Forecast by Therapy, 2017–2027
10.2.1. Glucagon-like peptide-1 (GLP-1) agonist
10.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
10.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
10.2.4. Insulin
10.2.5. Others
10.3. Market Value Forecast by Disease Type, 2017–2027
10.3.1. Type 1 Diabetes
10.3.2. Type 2 Diabetes
10.3.3. Gestational Diabetes
10.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
10.4. Market Value Forecast by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast by Country, 2017–2027
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. by Therapy
10.6.2. by Disease Type
10.6.3. by Distribution Channel
10.6.4. by Country
10.7. Key Trends
11. Asia Pacific Diabetes Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2. Market Value Forecast by Therapy, 2017–2027
11.2.1. Glucagon-like peptide-1 (GLP-1) agonist
11.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
11.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
11.2.4. Insulin
11.2.5. Others
11.3. Market Value Forecast by Disease Type, 2017–2027
11.3.1. Type 1 Diabetes
11.3.2. Type 2 Diabetes
11.3.3. Gestational Diabetes
11.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
11.4. Market Value Forecast by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast by Country, 2017–2027
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. by Therapy
11.6.2. by Disease Type
11.6.3. by Distribution Channel
11.6.4. by Country
11.7 Key Trends
12. Middle East & Africa Diabetes Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2. Market Value Forecast by Therapy, 2017–2027
12.2.1. Glucagon-like peptide-1 (GLP-1) agonist
12.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
12.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
12.2.4. Insulin
12.2.5. Others
12.3. Market Value Forecast by Disease Type, 2017–2027
12.3.1. Type 1 Diabetes
12.3.2. Type 2 Diabetes
12.3.3. Gestational Diabetes
12.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
12.4. Market Value Forecast by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast by Country, 2017–2027
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis
12.6.1. by Therapy
12.6.2. by Disease Type
12.6.3. by Distribution Channel
12.6.4. by Country
12.7. Key Trends
13. Latin America Diabetes Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Price Trend Analysis
13.1.4. Key Trends
13.2. Market Value Forecast by Therapy, 2017–2027
13.2.1. Glucagon-like peptide-1 (GLP-1) agonist
13.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
13.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
13.2.4. Insulin
13.2.5. Others
13.3. Market Value Forecast by Disease Type, 2017–2027
13.3.1. Type 1 Diabetes
13.3.2. Type 2 Diabetes
13.3.3. Gestational Diabetes
13.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
13.4. Market Value Forecast by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast by Country, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. by Therapy
13.6.2. by Disease Type
13.6.3. by Distribution Channel
13.6.4. by Country
13.7. Key Trends
14. Competition Landscape
14.1. Competition Matrix
14.2. Market Share Analysis by Company (2017)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. Novo Nordisk A/S
14.3.1.1. Company Description
14.3.1.2. Financial Overview
14.3.1.3. Strategic Overview
14.3.1.4. Recent Developments
14.3.1.5. SWOT ANALYSIS
14.3.2. Sanofi
14.3.2.1. Company Description
14.3.2.2. Financial Overview
14.3.2.3. Strategic Overview
14.3.2.4. Recent Developments
14.3.2.5. SWOT ANALYSIS
14.3.3. Merck & Co., Inc.
14.3.3.1. Company Description
14.3.3.2. Financial Overview
14.3.3.3. Strategic Overview
14.3.3.4. Recent Developments
14.3.3.5. SWOT ANALYSIS
14.3.4. Eli Lilly and company
14.3.4.1. Company Description
14.3.4.2. Financial Overview
14.3.4.3. Strategic Overview
14.3.4.4. Recent Developments
14.3.4.5. SWOT ANALYSIS
14.3.5. AstraZeneca
14.3.5.1. Company Description
14.3.5.2. Financial Overview
14.3.5.3. Strategic Overview
14.3.5.4. Recent Developments
14.3.5.5. SWOT ANALYSIS
14.3.6. Boehringer Ingelheim GmbH
14.3.6.1. Company Description
14.3.6.2. Financial Overview
14.3.6.3. Strategic Overview
14.3.6.4. Recent Developments
14.3.6.5. SWOT ANALYSIS
14.3.7. Johnson & Johnson
14.3.7.1. Company Description
14.3.7.2. Financial Overview
14.3.7.3. Strategic Overview
14.3.7.4. Recent Developments
14.3.7.5. SWOT ANALYSIS
14.3.8. Novartis AG
14.3.8.1. Company Description
14.3.8.2. Financial Overview
14.3.8.3. Strategic Overview
14.3.8.4. Recent Developments
14.3.8.5. SWOT ANALYSIS
14.3.9. Takeda Pharmaceutical Company Limited
14.3.9.1. Company Description
14.3.9.2. Financial Overview
14.3.9.3. Strategic Overview
14.3.9.4. Recent Developments
14.3.9.5. SWOT ANALYSIS
14.3.10. Bayer AG
14.3.10.1. Company Description
14.3.10.2. Financial Overview
14.3.10.3. Recent Developments
14.3.10.4. SWOT ANALYSIS
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers